reference/19029196

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19029196

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	274
issn	0008-543X 1097-0142
issueIdentifier	2
pageRange	269-274
publicationName	Cancer
startingPage	269
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_eb4f340a1767b2ff28113b9d3c67834b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d62f51386142d8e7576b9b70134d6e59 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_439eaa3a060cee9558b72b5b44408fde
bibliographicCitation	Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer. 2022 Jan 15;128(2):269–74. PMID: 34516660; PMCID: PMC8738121.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c6a7aa537a7f4fcb3766b21c520c32cd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b59ca39fbdfbdbe4ae87084aa11447a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f51620f52af69ceab1689e8be39c5457 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8184-7275 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40df825619529e19b4f08715ae8fe517 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79e07034484781dc8b6e93465ce794e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76f4b4c1af032775aaa1a1d2542aa2b2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e936e535dadeca235d09a9364e2aa1c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db6a5215ed97dc1c9a78bd201c91389c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb7d57ddbd3fc2a38362d32d1a9227b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3891dbbf9e66e0fcd347302a7aadbe11 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8503e1fbf599dd58d01d42e396fa2f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a3db638b0eeeaae7477c44e07d537556 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a8fee87dede95cb133b0cb919a0d082 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0833-952X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5d772ae9ea9562d5be9c70561806384 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60970449f1c62beea7b56f7f42339831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_835d267d98020513fb2e096a92afe13e http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1616-4478
date	2021-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC8738121 https://pubmed.ncbi.nlm.nih.gov/34516660 https://doi.org/10.1002/cncr.33911
isPartOf	https://portal.issn.org/resource/ISSN/1097-0142 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771 https://portal.issn.org/resource/ISSN/0008-543X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer
discusses	http://id.nlm.nih.gov/mesh/M0026444
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011471Q000628 http://id.nlm.nih.gov/mesh/D011471Q000175 http://id.nlm.nih.gov/mesh/D057832
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D017430 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D060787
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983

Total number of triples: 56.